Novartis pushes past manufacturing slowdown to launch second long-acting Copaxone copy

After last week’s FDA rejection for Sandoz’s generic Advair, Novartis’ copycat arm needed a win. And it got a key one Tuesday with the approval of generic 40-mg Copaxone.Original Article